Skip to main content
SpringerLink
Log in

Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review

  • Systematic Review
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Background

Psoriatic arthritis is a long-term inflammatory arthropathy occurring in a subgroup of patients with psoriasis. In addition to irreversible bone erosions, joint destruction, and skin manifestations, psoriatic arthritis is associated with numerous comorbid conditions. Over the last 5 years, new treatments emerged; the analysis and comparisons of their additional costs and the added benefits have become increasingly important to optimize the limited resources available.

Methods

A systematic literature review covering PubMed, EMBASE, and the Cochrane Library was performed from May 2012 to October 2017 focusing on the most recent evidence of costs, benefits, and burden of psoriatic arthritis and its treatments. All economic evaluations assessing the burden of patients with psoriatic arthritis and written in English were eligible for inclusion. We also performed an assessment of the quality of the studies.

Results

Of the 1652 references found in the literature search, nine cost-effectiveness analyses and 12 cost-of-illness studies were included in the current review. Patients with psoriatic arthritis incur substantially higher direct and indirect costs, as compared with patients with psoriasis without arthritis or patients with other inflammatory diseases. The cost of treatment with biologic therapies is the major predictor of the total cost. However, individuals with psoriatic arthritis are also affected by substantial productivity losses and indirect costs. Biologic therapies are generally cost effective vs. conventional therapies (e.g., synthetic drugs) for treating psoriatic arthritis.

Conclusions

Psoriatic arthritis is associated with a significant economic burden and biologic therapies contribute significantly to these costs. Biologic therapies are more effective than disease-modifying anti-rheumatic drugs for the symptoms and signs of psoriatic arthritis and for improving quality of life and inhibiting structural radiological damage. Therefore, biologic therapies are cost effective compared with conventional therapies: the increased direct cost associated with biologic drugs is offset by the significant improvement in the efficacy of treatments and in patient management of psoriatic arthritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2015;27(2):118–26.

    Article  Google Scholar 

  2. Kerschbaumer A, Fenzl K, Erlacher L, Aletaha D. An overview of psoriatic arthritis: epidemiology, clinical features, pathophysiology and novel treatment targets. Wien Klin Wochenschr. 2016;128:791–5.

    Article  CAS  Google Scholar 

  3. Haddad A, Zisman D. Comorbidities in patients with psoriatic arthritis. Rambam Maimonides Med J. 2017;8(1):e0004.

    Article  Google Scholar 

  4. Zhu B, Edson-Heredia E, Gatz JL, Guo J, Shuler CL. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study. Clin Ther. 2013;35:1376–85.

    Article  Google Scholar 

  5. Cortesi PA, Scalone L, D’Angiolella L, Belisari A, Fusco F, Olivieri I, Mantovani LG. Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. Clin Exp Rheumatol. 2012;30(4 Suppl. 33):S126–31.

    PubMed  Google Scholar 

  6. World Health Organization. Global report on psoriasis. 2016. http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf. Accessed 3 Feb 2018.

  7. Kawalec P, Malinowski KP, Pilc A. Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland. Rheumatol Int. 2016;36:1223–30.

    Article  Google Scholar 

  8. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499–510.

    Article  CAS  Google Scholar 

  9. Coates LC, Kavanaugh A, Ritchlin CT, GRAPPA Treatment Guideline Committee. Systematic review of treatments for psoriatic arthritis: 2014 update for the GRAPPA. J Rheumatol. 2014;41(11):2273–6.

    Article  Google Scholar 

  10. Ramiro S, Smolen JS, Landewé R, van der Heijde D, Dougados M, Emery P, de Wit M, Cutolo M, Oliver S, Gossec L. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2016;75(3):490–8.

    Article  CAS  Google Scholar 

  11. D’Angelo S, Tramontano G, Gilio M, Leccese P, Olivieri I. Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol. 2017;9:21–8.

    Article  Google Scholar 

  12. Olivieri I, D’Angelo S, Palazzi C, Padula A. Advances in the management of psoriatic arthritis. Nat Rev Rheumatol. 2014;10(9):531–42.

    Article  CAS  Google Scholar 

  13. Drummond M, Sculpher M, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press; 1997.

    Google Scholar 

  14. Löfvendahl S, Jöud A, Petersson IF, Theander E, Svensson Å, Carlsson KS. Income disparities in healthcare use remain after controlling for healthcare need: evidence from Swedish register data on psoriasis and psoriatic arthritis. Eur J Health Econ. 2017. https://doi.org/10.1007/s10198-017-0895-5 (Epub ahead of print).

  15. Greenberg JD, Palmer JB, Li Y, Herrera V, Tsang Y, Liao M. Healthcare resource use and direct costs in patients with ankylosing spondylitis and psoriatic arthritis in a large US cohort. J Rheumatol. 2016;43(1):88–96.

    Article  Google Scholar 

  16. Kvamme MK, Lie E, Kvien TK, Kristiansen IS. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry. Rheumatology (Oxford). 2012;51:1618–27.

    Article  Google Scholar 

  17. Palmer JB, Li Y, Herrera V, Liao M, Tran M, Ozturk ZE. Treatment patterns and costs for anti-TNFalpha biologic therapy in patients with psoriatic arthritis. BMC Musculoskelet Disord. 2016;17:261.

    Article  Google Scholar 

  18. Schwartzman S, Li Y, Zhou H, Palmer JB. Economic impact of biologic utilization patterns in patients with psoriatic arthritis. Clin Rheumatol. 2017;36(7):1579–88.

    Article  Google Scholar 

  19. Löfvendahl S, Petersson IF, Theander E, Svensson Å, Zhou C, Steen Carlsson K. Incremental costs for psoriasis and psoriatic arthritis in a population-based cohort in southern Sweden: is it all psoriasis-attributable morbidity? J Rheumatol. 2016;43(3):640–7.

    Article  Google Scholar 

  20. Raciborski F, Śliwczyński A, Kłak A, Kwiatkowska B, Brzozowska M, Tłustochowicz M. Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system: the case of Poland. Reumatologia. 2016;54:278–84.

    Article  Google Scholar 

  21. Kristensen LE, Jørgensen TS, Christensen R, Gudbergsen H, Dreyer L, Ballegaard C, et al. Societal costs and patients’ experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study. Ann Rheum Dis. 2017;76(9):1495–501.

    Article  Google Scholar 

  22. Al Sawah S, Foster SA, Goldblum OM, Malatestinic WN, Zhu B, Shi N, et al. Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis. J Med Econ. 2017;20(9):982–90.

    Article  Google Scholar 

  23. Kruntorádová K, Klimeš J, Šedová L, Štolfa J, Doležal T, Petříková A. Work productivity and costs related to patients with ankylosing spondylitis, rheumatoid arthritis, and psoriasis. Value Health Reg Issues. 2014;4:100–6.

    Article  Google Scholar 

  24. Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi M. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis. J Med Econ. 2013;16:479–89.

    Article  Google Scholar 

  25. O’Dwyer JL, Meads DM, Hulme CT, McParland L, Brown S, Coates LC, Moverley AR, Emery P, Conaghan PG, Helliwell PS. Cost-effectiveness of tight control of inflammation in early psoriatic arthritis: economic analysis of a multicenter randomized controlled trial. Arthritis Care Res (Hoboken). 2017. https://doi.org/10.1002/acr.23293 (Epub ahead of print).

  26. O’Connor J, Rice S, Smith A, Rodgers M, Lopez RR, Craig D, Woolacott N. The clinical and cost effectiveness of ustekinumab for the treatment of psoriatic arthritis: a critique of the evidence. Pharmacoeconomics. 2016;34:337–48.

    Article  Google Scholar 

  27. Cummins E, Asseburg C, Prasad M, Buchanan J, Punekar YS. Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. Eur J Health Econ. 2012;13:801–9.

    Article  Google Scholar 

  28. Strand V, Husni E, Griffith J, Zhou Z-Y, Signorovitch J, Ganguli A. Economic evaluation of timely versus delayed use of tumor necrosis factor inhibitors for treatment of psoriatic arthritis in the US. Rheumatol Ther. 2016;3(2):305–22.

    Article  Google Scholar 

  29. Yang TS, Chi CC, Wang SH, Lin JC, Lin KM. Cost-efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system. Int J Rheum Dis. 2016;19:1002–9.

    Article  Google Scholar 

  30. Corbett M, Chehadah F, Biswas M, Moe-Byrne T, Palmer S, Soares M, Walton M, Harden M, Ho P, Woolacott N, Bojke L. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technol Assess. 2017;21(56):1–326.

    Article  Google Scholar 

  31. Goeree R, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM, Gladman DD. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. J Med Econ. 2018;21(2):163–73.

    Article  Google Scholar 

  32. Olivieri I, Cortesi PA, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, Cantini F, Ciampichini R, Cutro MS, Mathieu A, Matucci-Cerinic M, Punzi L, Scarpa R, Mantovani LG, PACE Working Group. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. Clin Exp Rheumatol. 2016;34(1):68–75.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Centre on Public Health (CESP), University of Milan-Bicocca, Via G. Pergolesi 33, 20900, Monza, Italy

    Lucia Sara D’Angiolella, Paolo Angelo Cortesi, Alessandra Lafranconi, Mariangela Micale, Sveva Mangano, Giancarlo Cesana & Lorenzo Giovanni Mantovani

Authors
  1. Lucia Sara D’Angiolella
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paolo Angelo Cortesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandra Lafranconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mariangela Micale
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sveva Mangano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giancarlo Cesana
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lorenzo Giovanni Mantovani
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LSD and PAC wrote the first draft of the manuscript. MM and SM conducted literature searches. AL oversaw data assembly and collection and provided summaries of previous research studies. GC and LGM reviewed and supervised the activities. All authors have materially participated in the research and the manuscript preparation.

Corresponding author

Correspondence to Lorenzo Giovanni Mantovani.

Ethics declarations

Funding

No sources of funding were received for the preparation of this article.

Conflict of interest

Lucia S. D’Angiolella, Paolo Angelo Cortesi, Alessandra Lafranconi, Mariangela Micale, Sveva Mangano, Giancarlo Cesana, and Lorenzo G. Mantovani have no conflicts of interest directly relevant to the content of this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

D’Angiolella, L.S., Cortesi, P.A., Lafranconi, A. et al. Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review. PharmacoEconomics 36, 567–589 (2018). https://doi.org/10.1007/s40273-018-0618-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-018-0618-5

Search

Navigation